[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-18216":3,"doc-seo-18216":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"table_of_contents":24,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},18216,34359740700684,"Finn","https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487",7,"Healthcare","Enhanced Transdermal Delivery of Piroxicam via Nanocarriers","An optimized nano-niosomal piroxicam emulgel was formulated and characterized for particle size, polydispersity, zeta potential, drug entrapment and in vitro release, and transdermal permeation. Animal studies assessed pain, prostaglandin E2 in synovium, knee swelling and histopathology. A randomized double-blind trial compared analgesic effects of nano-niosomal piroxicam emulgel versus piroxicam gel. Results showed sustained release, markedly higher transdermal permeation and significant reductions in knee swelling and prostaglandin E2, with superior clinical pain relief.","cbCaiiWX0axfUZX3","https://ap.wps.com/l/cbCaiiWX0axfUZX3","pdf",1893225,80,1,20,"English","en","",1776590617,50,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":23,"slug":31,"title":13,"keywords":24,"description":14,"schema_data":32,"social_meta":67,"head_meta":70,"extra_data":72,"updated_unix":25},105,"enhanced-transdermal-delivery-of-piroxicam-via-nanocarriers",{"@graph":33,"@context":66},[34,51],{"@type":35,"itemListElement":36},"BreadcrumbList",[37,41,45,48],{"item":38,"name":39,"@type":40,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":42,"name":43,"@type":40,"position":44},"https://docshare.wps.com/document/","Document",2,{"item":46,"name":12,"@type":40,"position":47},"https://docshare.wps.com/document/healthcare/",3,{"item":49,"name":13,"@type":40,"position":50},"https://docshare.wps.com/document/enhanced-transdermal-delivery-of-piroxicam-via-nanocarriers/18216/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":60,"encodingFormat":58,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":38,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-06-02","2026-04-19",true,{"@type":63,"interactionType":64,"userInteractionCount":19},"InteractionCounter",{"@type":65},"ViewAction","https://schema.org",{"og:url":68,"og:type":69,"og:title":13,"og:site_name":56,"og:description":14},"https://docshare.wps.com/document/enhanced-transdermal-delivery-of-piroxicam-via-nanocarriers/18216","article",{"robots":71,"canonical":68},"index,follow",{"doc_id":7,"site_id":30}]